Gentler chemo before half-matched stem cell transplant for AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a gentler chemotherapy regimen (fludarabine and treosulfan) before a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for older or frailer patients with acute myeloid leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 75 years old, or between 18 and 59 if you cannot tolerate a standard stronger chemo regimen.
- You have acute myeloid leukemia (AML) that requires a stem cell transplant.
- Your leukemia is under control — meaning less than 5% cancer cells remain in your bone marrow after prior treatment.
- You have a half-matched (haploidentical) donor available for transplant.
- Your heart and kidneys work well enough (heart function at least 40%, kidney clearance at least 50 mL/min).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a less intense chemotherapy and radiation combination (called TMLI, fludarabine, and melphalan) before a stem cell transplant from a matched donor. The goal is to help prepare your body for the transplant while reducing side effects, so it may be a good option if you have high-risk MDS or AML and cannot tolerate the standard, more intensive conditioning regimen.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial is testing two different chemotherapy regimens (with one or two alkylating agents) before a stem cell transplant for people with acute myeloid leukemia or myelodysplastic syndrome. The goal is to find which conditioning treatment is safer and more effective.
This trial is testing a more targeted way to deliver radiation before a stem cell transplant, aiming to reduce side effects while helping the new cells engraft. It includes two different radiation doses, one for first-time transplant patients and another for those who have relapsed after a prior transplant.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.